Drug Trial Radar · NCT07806773
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer (NSCLC). The primary objectives of this study are to determine the safety and tolerability and effectiveness of TUB-040, and/or recommended Phase 2 dose (RP2D).
Conditions
- NSCLC
- Non Small Cell Lung Cancer
Interventions
TUB-040Drug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: From enrollment until 30 days after last dose of study drug
- Overall Response Rate (ORR)Time frame: Enrollment until approximately 80 days since last dose of study drug
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
START Los Angeles
Los Angeles, California
START New Jersey
East Brunswick, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.